ionis-apo(a)-lrx
Nucleic acidexperimental
Clinical trial activity
8 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
3
Phase 4
0
Earliest trial started Apr 1, 2015 (NCT02414594)
Timeline
Indications
Mechanism of action
- Apolipoprotein A-IINHIBITOR
APOA1 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- ionis-apo(a)-lrx
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06813911 | Phase 3 | May 28, 2025 | Novartis |
| NCT06875973 | Phase 3 | May 20, 2025 | Novartis |
| NCT05900141 | Phase 3 | Sep 29, 2023 | Novartis |
| NCT05026996 | Phase 1 | Nov 11, 2021 | Novartis |
| NCT04993664 | N/A | Oct 1, 2021 | University of Ljubljana |
| NCT05337878 | Phase 1 | Oct 15, 2018 | Ionis Pharmaceuticals, Inc. |
| NCT02414594 | Phase 1 | Apr 1, 2015 | Akcea Therapeutics, Ionis Pharmaceuticals, Inc. |
| NCT07000695 | N/A | — | Novartis |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 5 | 5 | 3 | 2021 |
| Ionis Pharmaceuticals, Inc. | For profit | 2 | 2 | 1 | 2015 |
| Akcea Therapeutics | For profit | 1 | 0 | 1 | 2015 |
| University of Ljubljana | Academic/Hospital | 1 | 1 | 1 | 2021 |
4 organizations
Page 1 / 1